REG - Morgan Stanley&CoLLC Avadel Pharma plc - Form 38.5_A - Avadel Pharmaceuticals plc

Avadel PharmaceuticalsAnnouncement

12/12/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251212:nRSL4012La&default-theme=true

RNS Number : 4012L  Morgan Stanley & Co. LLC  12 December 2025

 

FORM 38.5(a) (EPT/RI)

 

IRISH TAKEOVER PANEL

 

DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH

TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

BY A CONNECTED EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS AND DEALING IN

A CLIENT-SERVING CAPACITY

 

1.             KEY INFORMATION

 

 

 (a)   Name of exempt principal trader:                                         Morgan Stanley & Co. LLC
 (b)   Name of offeror/offeree in relation to whose relevant securities this    Avadel Pharmaceuticals plc
 form relates:

 Use a separate form for each offeror/offeree
 (c)   Name of the party to the offer with which exempt principal trader is     Avadel Pharmaceuticals plc
 connected: (Note 1)
 (d)   Date dealing undertaken:                                                 11 December 2025
 (e)   In addition to the company in 1(b) above, is the exempt principal        N/A
 trader also making disclosures in respect of any other party to the offer?

 If it is a cash offer or possible cash offer, state "N/A"

 

2.             DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)

 

Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

 

 

(a)           Purchases and sales

 

 Class of              Purchases/   Total        Highest       Lowest
 relevant              sales
number of   price per     price per
 security                           securities   unit paid/    unit paid/
 (Note 3)                                        received      received
 0.01 ordinary shares  PURCHASES    149,704      21.5500 USD   21.3800 USD
 0.01 ordinary shares  SALES        149,749      21.5200 USD   21.3800 USD

 

(b)           Cash-settled derivative transactions

 

 Class of    Product       Nature of dealing         Number of    Price per
 relevant    description   e.g. opening/closing      reference
unit (Note 5)
 security    e.g. CFD      a long/short position,    securities
                           increasing/reducing a     (Note 4)
                           long/short position
 N/A         N/A           N/A                       N/A          N/A

 

(c)           Stock-settled derivative transactions (including
options)

 

(i)            Writing, selling, purchasing or varying

 

 Class of    Product            Writing,       Number        Exercise     Type         Expiry  Option
 relevant    description        purchasing,    of            price per     e.g.
date   money
 security    e.g. call option   selling,       securities    unit         American,            paid/
                                varying etc.   to which                   European             received
                                               option                     etc.                 per unit
                                               relates
                                               (Note 4)
 N/A         N/A                N/A            N/A           N/A          N/A          N/A     N/A

 

(ii)           Exercise

 

 Class of    Product            Exercising/   Number of    Exercise price
 relevant    description        exercised     securities
per unit
 security    e.g. call option   against                    (Note 5)
 N/A         N/A                N/A           N/A          N/A

 

(d)           Other dealings (including transactions in respect of
new securities)

 

 Class of relevant security  Nature of             Details  Price per unit
                             dealing                        (if applicable)
                             e.g. subscription,             (Note 5)
                             conversion,
                             exercise
 N/A                         N/A                   N/A      N/A

 

 

3.             OTHER INFORMATION

 

(a)           Indemnity and other dealing arrangements

 

 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the exempt
 principal trader making the disclosure and any party to the offer or any
 person acting in concert with a party to the offer:

 Irrevocable commitments and letters of intent should not be included. If there
 are no such agreements, arrangements or understandings, state "none"
 NONE

 

(b)           Agreements, arrangements or understandings relating to
options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced. If none, this should be
 stated.
 NONE

 

 Date of disclosure:  12 December 2025
 Contact name:        Claire Gordon
 Telephone number:    +44 141 245-8893

 

Public disclosures under Rule 38 of the Rules must be made to a Regulatory
Information Service.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPTTBMTMTJBBIA



            Copyright 2019 Regulatory News Service, all rights reserved